Stephens & Co. Maintains Overweight on TransMedics Gr, Raises Price Target to $178
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst George Sellers maintains an Overweight rating on TransMedics Group (NASDAQ:TMDX) and raises the price target from $151 to $178.
August 02, 2024 | 6:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stephens & Co. analyst George Sellers maintains an Overweight rating on TransMedics Group (NASDAQ:TMDX) and raises the price target from $151 to $178.
The raised price target and maintained Overweight rating from a reputable analyst are positive signals for investors, likely leading to a short-term increase in TMDX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100